Method for prediction of prognosis of sepsis
Disclosed is a prediction method for the prognosis of sepsis comprising measuring an sCD14-ST level in a sample. sCD14-ST, to be measured in the present invention, is a marker superior to procalcitonin, known as a marker to predict the prognosis in sepsis patients.
1. A method for predicting a prognosis of sepsis and treating sepsis, the method comprising:
measuring an sCD14-ST level in a sample collected from a human patient suspected of having sepsis or a sepsis human patient, said sample being selected from the group consisting of whole blood, plasma and serum;
predicting a prognosis of sepsis of the human patient when the sCD14-ST level is higher compared to that of a healthy individual; and
treating the human patient for sepsis with administration of a renal replacement therapy based upon the predicted prognosis of sepsis.
2. The method according to claim 1 , wherein the sCD14-ST level is correlated with a quantile group, which is determined in which patients are classified and differentiated based on sepsis severity in advance, in the predicting step.
3. The method according to claim 1 , wherein the sCD14-ST level is measured by an immunological measuring method.
4. The method according to claim 1 , wherein the human patient is treated with antibiotics based on the predicted prognosis.
5. The method according to claim 1 , wherein sepsis is treated by the use of a member selected from the group consisting of antimicrobial agents, fluid therapy, vasoconstrictors, cardiac drugs, steroid therapy, blood preparations, blood sugar control, blood purification methods, surgery, endotoxin adsorption therapy, and γ-globulin preparations.
6. The method according to claim 2 , wherein the quantile level is a threshold value.
7. The method according to claim 6 , wherein the threshold value is 920 pg/mL.
8. The method according to claim 2 , wherein the quantile level is a member selected from level 1 of 177-512 pg/mL, level 2 of 524-927 pg/mL, level 3 of 950-1810 pg/mL, and level 4 of 1858 pg/mL or more.
9. The method of claim 3 , wherein the immunological method comprises a polyclonal antibody labeled with alkaline phosphatase and a monoclonal antibody.
10. The method of claim 9 , wherein the monoclonal antibody is a F1031-8-3 antibody immobilized on magnetic particles.
11. The method of claim 1 , wherein the prediction is a prediction of a mortality rate within 5 to 30 days of admission.